ACM
DYN icon

Atika Capital Management’s Dyne Therapeutics DYN Stock Holding History

Atika Capital Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-181,500
Closed -$6.41M – 93
2024
Q2 		$6.41M Buy
181,500
+6,500
+4% +$189K 0.63% 54
2024
Q1 		$4.97M Buy
+175,000
New +$3.96M 0.49% 68

Other funds holding DYN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Atika Capital Management's DYN Position: Q3 2024 in Review

Atika Capital Management sold out of Dyne Therapeutics (DYN) in Q3 2024, closing a stake of 181,500 shares — an estimated $6.41M sold.

Atika Capital Management first reported a position in DYN in Q1 2024 and held it in 2 quarters. The position peaked at $6.41M in Q2 2024. 200 funds tracked by Wall St. Rank hold DYN as of Q3 2024.

  • Atika Capital Management reported no remaining Dyne Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Atika Capital Management sold 181,500 Dyne Therapeutics shares in Q3 2024, an estimated $6.41M.
  • Atika Capital Management first reported a position in Dyne Therapeutics in Q1 2024 and held it in 2 quarters.
  • Atika Capital Management's Dyne Therapeutics position peaked at $6.41M in Q2 2024.
  • 200 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q3 2024.

Based on Atika Capital Management's 13F filing for Q3 2024, filed 13 Nov 2024.